Article
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.
Nature communications - 17 Sept 2022
Yang Yandan, Bolomsky Arnold, Oellerich Thomas, Chen Ping, Ceribelli Michele, Häupl Björn, Wright George W, Phelan James D, Huang Da Wei, Lord James W, Van Winkle Callie K, Yu Xin, Wisniewski Jan, Wang James Q, Tosto Frances A, Beck Erin, Wilson Kelli, McKnight Crystal, Travers Jameson, Klumpp-Thomas Carleen, Smith Grace A, Pittaluga Stefania, Maric Irina, Kazandjian Dickran, Thomas Craig J, Young Ryan M
Abstract excerpt
Oncogenic RAS mutations are common in multiple myeloma (MM), an incurable malignancy of plasma cells. However, the mechanisms of pathogenic RAS signaling in this disease remain enigmatic and difficult to inhibit therapeutically. We employ an unbiased proteogenomic approach to dissect RAS signaling in MM. We discover that mutant isoforms of RAS organize a signaling complex with the amino acid transporter, SLC3A2,...
Topics
- Amino Acids
- Genes, ras
- Humans
- Mechanistic Target of Rapamycin Complex 1
- Mitogen-Activated Protein Kinase Kinases
- Multiple Myeloma
- Mutation
- Protein Isoforms